NLS Agreement

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia.

The two companies have expanded their partnership to accelerate the development of the Dispersome technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules.

Navamedic has partnered with Alex Therapeutics to aid in Parkinson’s treatment management.

Rokote Laboratories Finland has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate expressing a modified spike protein of severe acute respiratory coronavirus 2. 3PBIOVIAN will provide Rokote Laboratories with Drug Substance and Drug Product to bring the intranasal FINCoVac 2.1 vaccine into Phase I clinical studies. The […]

The Swedish biotech company has entered into a research collaboration agreement with Eli Lilly and Company to apply its AbiProt technology to generate antibodies against a well-validated target protein. This partnership aims to accelerate research and development of innovative treatments and, if successful, will generate milestone payments and royalty income, states the company. Under the […]

Xbrane Biopharma will regain full rights to BIIB801 following a decision by Biogen to terminate the commercialization and license agreement between the companies. All rights to the product will be reverted to Xbrane. An out-licensing process to identify a new partner has been initiated. BIIB801 is a preclinical monoclonal antibody fragment that is a proposed […]